Female patient characteristics
| Participants (n = 8) | |
|---|---|
| Age in years, median (IQR) | 54.0 (41–59) |
| Menopausal status, n (%) | |
| Pre/perimenopausal | 5 (62.5%) |
| Post | 3 (37.5%) |
| Clinical tumor stage, n (%) | |
| cT0 | 0 (0%) |
| cT1 | 2 (25%) |
| cT2 | 6 (75%) |
| Clinical lymph node status, n (%) | |
| Negative | 4 (50%) |
| Positive | 4 (50%) |
| Stage, n (%) | |
| II | 6 (75%) |
| III | 2 (25%) |
| HER2 status, n (%) | |
| 3+ at IHC | 8 (100%) |
| ER status, n (%) | |
| Positive (≥10%) | 4 (50%) |
| Negative (<10%) | 4 (50%) |
| PR status, n (%) | |
| Positive (≥10%) | 2 (25%) |
| Negative (<10%) | 6 (75%) |
| Tumor grade, n (%) | |
| Grade 2 | 1 (12.5%) |
| Grade 3 | 7 (87.5%) |
| Histology, n (%) | |
| NST/ductal | 8 (100%) |
| Pathologic outcome, n (%) | |
| Pathologic complete response (ypT0/is, N0) | 5 (62.5%) |
| No pathologic complete response | 3 (37.5%) |
ER, estrogen receptor; IHC, immunohistochemistry; IQR, interquartile range; NST, no special type; PR, progesterone receptor.